Literature DB >> 7514021

Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin.

A Lopez-Anaya1, C Dawson, C Gonzales, M Bacolod, V Kishore.   

Abstract

The effect of nutritional copper (Cu) deficiency on the antiinflammatory activity and pharmacokinetics of aspirin (ASA) was investigated in rats. Male, weanling Sprague-Dawley rats were fed either a Cu-deficient (CuD) or Cu-sufficient (CuS) diet for 49-50 d. The antiinflammatory activity of ASA was studied using the carrageenan-induced paw edema (CPE) test. ANOVA analyses of edema volumes at 2, 3, 4, 5, and 21 h postcarrageenan indicated significant differences between groups. The percent inhibition of edema due to ASA treatment in CuS was lower than that in CuD rats at 5 h, AUC5h, and AUC21h. ASA was found to be significantly more effective in inhibiting the CPE in CuD rats when compared to the CuS rats. Thus, we hypothesized that the increase in ASA's antiinflammatory activity in CuD rats was a result of a decrement in its elimination during nutritional Cu deficiency. The elimination of ASA in CuD and CuS rats was studied using an iv dose of 200 mg/kg. Concentrations of ASA and salicylic acid (SA) were determined in blood; whereas the concentrations of SA, salicylic phenol-glucuronide (SPG), and salicyluric acid (SUA) were determined in urine by HPLC. The results of the pharmacokinetic analyses from blood and urinary data indicated no significant differences in the disposition of ASA between CuD and CuS rats. For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively. Thus, contrary to our hypothesis, the enhanced antiinflammatory activity of ASA in CuD rats does not appear to be mediated via a decrement in the elimination of the drug. In addition, plasma ASA-esterase activity was found to be independent of Cu nutritional status.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514021     DOI: 10.1007/bf02950789

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  30 in total

1.  Effect of dimethyl sulfoxide on enlarged hearts of copper-deficient rats.

Authors:  J T Saari; D M Medeiros
Journal:  Biol Trace Elem Res       Date:  1991-12       Impact factor: 3.738

2.  Human liver and plasma aspirin esterase.

Authors:  F M Williams; E M Mutch; E Nicholson; H Wynne; P Wright; D Lambert; M D Rawlins
Journal:  J Pharm Pharmacol       Date:  1989-06       Impact factor: 3.765

3.  The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters.

Authors:  R Eisenthal; A Cornish-Bowden
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

4.  A reappraisal of the anti-inflammatory activity of copper.

Authors:  G B West
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

5.  Studies on aspirin esterase of human serum.

Authors:  M Morikawa; M Inoue; M Tsuboi; M Sugiura
Journal:  Jpn J Pharmacol       Date:  1979-08

6.  Carrageenan foot edema test.

Authors:  I G Otterness; P F Moore
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

7.  Circadian variation of liver esterases.

Authors:  R D Bhattacharya; H von Mayersbach
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1981

8.  Effect of excess and deficient copper intake on rat liver microsomal enzyme activity.

Authors:  A E Moffitt; S D Murphy
Journal:  Biochem Pharmacol       Date:  1973-06-15       Impact factor: 5.858

9.  Gastrointestinal and hepatic first-pass metabolism of aspirin in rats.

Authors:  K Iwamoto; M Takei; J Watanabe
Journal:  J Pharm Pharmacol       Date:  1982-03       Impact factor: 3.765

10.  Nonlinear pharmacokinetics of aspirin in rats.

Authors:  M G Wientjes; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.